Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Streptococcal Infections | 24 | 2024 | 184 | 5.870 |
Why?
|
| Streptococcus agalactiae | 28 | 2024 | 202 | 5.040 |
Why?
|
| Pregnancy Complications, Infectious | 14 | 2025 | 529 | 2.800 |
Why?
|
| Streptococcal Vaccines | 6 | 2024 | 47 | 2.360 |
Why?
|
| Immunoglobulin G | 18 | 2024 | 231 | 2.160 |
Why?
|
| Serogroup | 10 | 2024 | 150 | 1.580 |
Why?
|
| Antibodies, Viral | 13 | 2023 | 284 | 1.580 |
Why?
|
| Pregnancy | 31 | 2025 | 1862 | 1.520 |
Why?
|
| Antibodies, Bacterial | 14 | 2023 | 153 | 1.440 |
Why?
|
| Rectum | 6 | 2020 | 22 | 1.330 |
Why?
|
| Vagina | 7 | 2022 | 91 | 1.330 |
Why?
|
| Spike Glycoprotein, Coronavirus | 6 | 2024 | 101 | 1.290 |
Why?
|
| Infant, Newborn | 23 | 2025 | 1479 | 1.230 |
Why?
|
| Humans | 58 | 2025 | 14537 | 1.130 |
Why?
|
| Female | 40 | 2025 | 9103 | 1.020 |
Why?
|
| Vaccines | 5 | 2023 | 86 | 0.920 |
Why?
|
| Dried Blood Spot Testing | 1 | 2021 | 24 | 0.760 |
Why?
|
| Adult | 22 | 2025 | 5913 | 0.760 |
Why?
|
| Polysaccharides, Bacterial | 4 | 2023 | 35 | 0.740 |
Why?
|
| HIV Infections | 11 | 2024 | 5097 | 0.720 |
Why?
|
| Infant | 17 | 2025 | 2244 | 0.640 |
Why?
|
| Anti-Bacterial Agents | 5 | 2024 | 293 | 0.590 |
Why?
|
| Immunity, Humoral | 3 | 2022 | 42 | 0.580 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2022 | 472 | 0.570 |
Why?
|
| Bacterial Adhesion | 1 | 2016 | 6 | 0.530 |
Why?
|
| Immunity, Cellular | 1 | 2016 | 25 | 0.520 |
Why?
|
| South Africa | 21 | 2024 | 7596 | 0.510 |
Why?
|
| Carrier State | 2 | 2019 | 92 | 0.500 |
Why?
|
| Vaccination | 8 | 2024 | 365 | 0.470 |
Why?
|
| Membrane Proteins | 4 | 2024 | 36 | 0.470 |
Why?
|
| Young Adult | 12 | 2022 | 2498 | 0.450 |
Why?
|
| Bacterial Capsules | 5 | 2022 | 33 | 0.440 |
Why?
|
| Infant, Newborn, Diseases | 3 | 2019 | 73 | 0.430 |
Why?
|
| Culture Media | 1 | 2013 | 15 | 0.430 |
Why?
|
| Milk, Human | 2 | 2025 | 23 | 0.410 |
Why?
|
| Premature Birth | 2 | 2022 | 80 | 0.380 |
Why?
|
| Antibodies, Neutralizing | 6 | 2023 | 303 | 0.370 |
Why?
|
| Bacterial Vaccines | 2 | 2024 | 13 | 0.360 |
Why?
|
| Cytomegalovirus Infections | 2 | 2021 | 23 | 0.350 |
Why?
|
| Seroepidemiologic Studies | 7 | 2023 | 109 | 0.330 |
Why?
|
| Immunity, Maternally-Acquired | 3 | 2023 | 40 | 0.310 |
Why?
|
| Whole Genome Sequencing | 2 | 2024 | 44 | 0.280 |
Why?
|
| Immunogenicity, Vaccine | 3 | 2022 | 103 | 0.270 |
Why?
|
| Extracellular Vesicles | 1 | 2025 | 5 | 0.240 |
Why?
|
| Latex Fixation Tests | 2 | 2015 | 8 | 0.240 |
Why?
|
| Neonatal Sepsis | 1 | 2025 | 29 | 0.240 |
Why?
|
| Aged | 4 | 2022 | 1740 | 0.240 |
Why?
|
| Computer Simulation | 1 | 2024 | 56 | 0.240 |
Why?
|
| Adolescent | 7 | 2022 | 2985 | 0.230 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2024 | 3 | 0.230 |
Why?
|
| Virulence Factors | 1 | 2024 | 18 | 0.230 |
Why?
|
| Klebsiella Infections | 1 | 2024 | 13 | 0.230 |
Why?
|
| Postpartum Period | 1 | 2024 | 85 | 0.230 |
Why?
|
| Pregnant Women | 4 | 2020 | 89 | 0.230 |
Why?
|
| Klebsiella pneumoniae | 1 | 2024 | 39 | 0.220 |
Why?
|
| Case-Control Studies | 6 | 2022 | 480 | 0.220 |
Why?
|
| Bacteriological Techniques | 2 | 2015 | 54 | 0.220 |
Why?
|
| Bacterial Proteins | 1 | 2024 | 119 | 0.220 |
Why?
|
| Immunization | 1 | 2023 | 63 | 0.220 |
Why?
|
| Immunization Schedule | 2 | 2021 | 81 | 0.210 |
Why?
|
| Chorioamnionitis | 1 | 2022 | 10 | 0.210 |
Why?
|
| Chlorides | 1 | 2022 | 2 | 0.200 |
Why?
|
| Zinc Compounds | 1 | 2022 | 2 | 0.200 |
Why?
|
| Africa South of the Sahara | 1 | 2023 | 353 | 0.200 |
Why?
|
| Viral Vaccines | 1 | 2022 | 24 | 0.200 |
Why?
|
| Cross-Sectional Studies | 6 | 2025 | 1422 | 0.190 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2021 | 11 | 0.190 |
Why?
|
| Tetanus | 1 | 2021 | 10 | 0.190 |
Why?
|
| Diphtheria | 1 | 2021 | 16 | 0.190 |
Why?
|
| Cross Infection | 1 | 2021 | 52 | 0.190 |
Why?
|
| Haemophilus Vaccines | 1 | 2021 | 41 | 0.180 |
Why?
|
| Middle Aged | 6 | 2022 | 3601 | 0.180 |
Why?
|
| Prevalence | 3 | 2025 | 1192 | 0.180 |
Why?
|
| Immunization, Secondary | 1 | 2021 | 72 | 0.180 |
Why?
|
| Prospective Studies | 3 | 2022 | 1160 | 0.170 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2020 | 54 | 0.170 |
Why?
|
| Rubella | 1 | 2019 | 5 | 0.170 |
Why?
|
| Rubella virus | 1 | 2019 | 8 | 0.170 |
Why?
|
| Measles | 1 | 2019 | 36 | 0.170 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 150 | 0.160 |
Why?
|
| Incidence | 2 | 2023 | 685 | 0.160 |
Why?
|
| T-Lymphocytes | 3 | 2024 | 65 | 0.150 |
Why?
|
| Influenza Vaccines | 1 | 2020 | 144 | 0.150 |
Why?
|
| Risk Factors | 3 | 2019 | 1475 | 0.150 |
Why?
|
| Male | 7 | 2025 | 6754 | 0.150 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2017 | 5 | 0.150 |
Why?
|
| Bayes Theorem | 3 | 2023 | 81 | 0.140 |
Why?
|
| Antibody Formation | 3 | 2022 | 61 | 0.140 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2016 | 10 | 0.130 |
Why?
|
| Double-Blind Method | 3 | 2021 | 272 | 0.130 |
Why?
|
| Influenza, Human | 1 | 2020 | 374 | 0.130 |
Why?
|
| Antigens, Surface | 1 | 2015 | 11 | 0.130 |
Why?
|
| Phagocytosis | 1 | 2015 | 15 | 0.120 |
Why?
|
| Global Health | 1 | 2016 | 193 | 0.120 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2014 | 30 | 0.120 |
Why?
|
| Random Allocation | 1 | 2013 | 23 | 0.110 |
Why?
|
| Vaccines, Combined | 2 | 2023 | 34 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 385 | 0.100 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2024 | 135 | 0.100 |
Why?
|
| Child | 3 | 2022 | 2242 | 0.090 |
Why?
|
| Vaccines, Conjugate | 2 | 2023 | 171 | 0.090 |
Why?
|
| Immunoassay | 2 | 2024 | 28 | 0.090 |
Why?
|
| Longitudinal Studies | 2 | 2022 | 435 | 0.090 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2022 | 198 | 0.090 |
Why?
|
| HIV-1 | 2 | 2017 | 1260 | 0.090 |
Why?
|
| Pandemics | 2 | 2023 | 296 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2021 | 967 | 0.070 |
Why?
|
| Ethiopia | 1 | 2025 | 18 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2025 | 34 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 48 | 0.060 |
Why?
|
| China | 1 | 2024 | 21 | 0.060 |
Why?
|
| Genome, Bacterial | 1 | 2024 | 32 | 0.060 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2024 | 37 | 0.060 |
Why?
|
| Immunity | 1 | 2023 | 10 | 0.060 |
Why?
|
| Polysaccharides | 1 | 2024 | 45 | 0.060 |
Why?
|
| Biomarkers | 2 | 2015 | 327 | 0.060 |
Why?
|
| Receptors, Fc | 1 | 2023 | 10 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2023 | 67 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2024 | 151 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2024 | 217 | 0.050 |
Why?
|
| Ribs | 1 | 2023 | 4 | 0.050 |
Why?
|
| Antibodies, Blocking | 1 | 2023 | 9 | 0.050 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2023 | 7 | 0.050 |
Why?
|
| Immunoglobulin A | 1 | 2023 | 39 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 60 | 0.050 |
Why?
|
| Placenta | 1 | 2022 | 44 | 0.050 |
Why?
|
| Birth Weight | 1 | 2022 | 80 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2022 | 17 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2022 | 117 | 0.050 |
Why?
|
| Public Health Surveillance | 1 | 2022 | 52 | 0.050 |
Why?
|
| Serotyping | 1 | 2022 | 66 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2022 | 55 | 0.050 |
Why?
|
| Blood Donors | 1 | 2021 | 19 | 0.050 |
Why?
|
| Retrospective Studies | 1 | 2025 | 799 | 0.050 |
Why?
|
| Neutralization Tests | 1 | 2022 | 108 | 0.050 |
Why?
|
| Cross Reactions | 1 | 2021 | 44 | 0.050 |
Why?
|
| Risk Reduction Behavior | 1 | 2021 | 39 | 0.050 |
Why?
|
| Safety | 1 | 2021 | 34 | 0.050 |
Why?
|
| Poliovirus Vaccine, Inactivated | 1 | 2021 | 17 | 0.050 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2021 | 28 | 0.050 |
Why?
|
| Vaccine Potency | 1 | 2021 | 16 | 0.050 |
Why?
|
| Hepatitis B Vaccines | 1 | 2021 | 40 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2020 | 17 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2021 | 39 | 0.050 |
Why?
|
| United Kingdom | 1 | 2020 | 33 | 0.050 |
Why?
|
| Brazil | 1 | 2020 | 47 | 0.050 |
Why?
|
| Asymptomatic Infections | 1 | 2021 | 34 | 0.050 |
Why?
|
| Clindamycin | 1 | 2020 | 3 | 0.050 |
Why?
|
| Vancomycin | 1 | 2020 | 6 | 0.040 |
Why?
|
| Hemagglutinins | 1 | 2020 | 5 | 0.040 |
Why?
|
| Erythromycin | 1 | 2020 | 12 | 0.040 |
Why?
|
| Multilocus Sequence Typing | 1 | 2020 | 19 | 0.040 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2020 | 13 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2021 | 175 | 0.040 |
Why?
|
| Penicillins | 1 | 2020 | 25 | 0.040 |
Why?
|
| Levofloxacin | 1 | 2020 | 21 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 244 | 0.040 |
Why?
|
| Mutation | 1 | 2021 | 306 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 80 | 0.040 |
Why?
|
| Cytomegalovirus | 1 | 2019 | 24 | 0.040 |
Why?
|
| Saliva | 1 | 2019 | 22 | 0.040 |
Why?
|
| Measles Vaccine | 1 | 2019 | 34 | 0.040 |
Why?
|
| Health Personnel | 1 | 2021 | 231 | 0.040 |
Why?
|
| Age Factors | 1 | 2019 | 370 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2020 | 889 | 0.040 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2017 | 18 | 0.030 |
Why?
|
| Mothers | 1 | 2019 | 195 | 0.030 |
Why?
|
| Animals | 1 | 2020 | 1081 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2017 | 133 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 171 | 0.030 |
Why?
|
| Fimbriae, Bacterial | 1 | 2015 | 10 | 0.030 |
Why?
|
| Adhesins, Bacterial | 1 | 2015 | 12 | 0.030 |
Why?
|
| Poverty | 1 | 2016 | 152 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 87 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 2015 | 32 | 0.030 |
Why?
|
| Immunologic Techniques | 1 | 2014 | 4 | 0.030 |
Why?
|
| Viral Load | 1 | 2017 | 819 | 0.030 |
Why?
|
| Mesonephroma | 1 | 1982 | 1 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 1982 | 15 | 0.010 |
Why?
|